Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically ...

BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BHB810, a novel, ...

In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...

InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical ...

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global ...

New Study Advances cDC1-Based Cancer Immunotherapy / Akata Saha, Allison Dyevoich, Bhakti Patel, Btnl2 Protein, cancer, CD4 T ...

Faron Enrolls First Patient in BEXAR Trial of Bexmarilimab for Metastatic Soft-Tissue Sarcoma / BEXAR, Bexmarilimab, Clever-1 ...

A new iPSC-derived dendritic cell platform uses patient tumor material to prime T cells against multiple cancer targets.

The "Global VISTA Inhibitor Market Opportunities & Clinical Trials Insight 2026" has been added to ResearchAndMarkets.com's offering.Thereport delivers a consolidated view of market drivers, ...

Researchers in Purdue University's College of Pharmacy have developed and validated a new series of small-molecule inhibitors ...

Zhong-Yin Zhang leads a team that has developed and validated a novel series of small-molecule inhibitors that promote ...